Neuronetics Inc. has developed a device for treating serious depression in pharmaco-resistant patients. The company believes that its repetitive Transcranial Magnetic Stimulation technology, delivered noninvasively in an outpatient setting, is free of the serious side effects that accompany antidepressant drugs; moreover that it will be more effective and much safer for patients than the only currently approved neuromodulation technology for depression: electroconvulsive therapy.
One Great Valley Parkway, Suite 2
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Through this partnership, data stored in LibreView – Abbott’s cloud-based diabetes data management system – can automatically flow into Epic, allowing clinicians using Epic to view a patient’s CGM data before, during and after visits without toggling between systems or requesting manual uploads.
Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.
HistoSonics, which developed a noninvasive technology to destroy tumor cells, reports 90% local tumor control at 12-month follow-up in the #HOPE4Liver Trial. The Edison System, cleared by the US FDA in late 2023, is also being evaluated for kidney and pancreatic tumors. CEO Mike Blue said the medtech is financially secure but watching public markets as it considers an IPO.
